We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Stada Arzneimi Namen (CE) | USOTC:STDAF | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 110.42 | 0.00 | 01:00:00 |
From Jul 2019 to Jul 2024
By Carlo Martuscelli
German pharmaceutical business Stada Arzneimittel AG said Monday that it is acquiring a portfolio of consumer health-care brands from GlaxoSmithKline for an undisclosed amount.
Stada, which specializes in generic and over-the-counter medicines, said it was purchasing 15 brands, including those specializing in vitamins, cold treatments, and sore throat medication.
The deal is expected to close in the second quarter of the year.
GlaxoSmithKline, a FTSE-100 listed drug maker, announced a strategic re-organization earlier in the month aimed at increasing its focus on high-end research. In December 2018, the company said it would combine its consumer-health division with US rival Pfizer's, to eventually spin off the joint venture. The two-year program aims to prepare for the split in 2022, leaving behind a research-focused biopharmaceutical company.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com
(END) Dow Jones Newswires
February 24, 2020 07:31 ET (12:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Stada Arzneimi Namen (CE) Chart |
1 Month Stada Arzneimi Namen (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
